Department of Internal Medicine, University of Nevada, Las Vegas, Las Vegas, NV, USA.
Adv Exp Med Biol. 2024;1448:399-408. doi: 10.1007/978-3-031-59815-9_27.
Patients with established rheumatic disorders may develop complications of macrophage activation syndrome due to severe flares of the underlying disease (adult-onset Still's disease, SLE); however, in most other rheumatic disorders, MAS develops in association with identified viral or other infectious triggers. It is therefore important to pursue appropriate studies to identify potential infectious triggers in rheumatic disease patients who develop MAS. Management is best directed toward treatment of the triggering infections and combinations of high-dose corticosteroids, calcineurin inhibitors, and biologic therapies targeting IL-1 and/or IL-6 to suppress the associated cytokine storm.
患有明确风湿性疾病的患者可能会因基础疾病(成人斯蒂尔病、SLE)的严重发作而发生巨噬细胞活化综合征的并发症;然而,在大多数其他风湿性疾病中,MAS 与已识别的病毒或其他感染性触发因素相关。因此,重要的是对发生 MAS 的风湿性疾病患者进行适当的研究以确定潜在的感染性触发因素。治疗的最佳方法是针对触发感染以及大剂量皮质类固醇、钙调磷酸酶抑制剂和针对 IL-1 和/或 IL-6 的生物疗法联合治疗,以抑制相关的细胞因子风暴。